- Home
- VRNS vs CELC Comparison
VRNS vs CELC Comparison
Compare VRNS & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRNS | CELC |
|---|---|---|
| Founded | 2004 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.2B |
| IPO Year | 2013 | 2017 |
Fundamental Metrics
Financial Performance| Metric | VRNS | CELC |
|---|---|---|
| Price | $43.94 | $93.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 9 |
| Target Price | $42.75 | ★ $112.56 |
| AVG Volume (30 Days) | ★ 1.8M | 990.6K |
| Earning Date | 04-28-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $270,288,000.00 | N/A |
| Revenue This Year | $18.87 | N/A |
| Revenue Next Year | $17.77 | $720.19 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 24.35 | N/A |
| 52 Week Low | $19.70 | $44.42 |
| 52 Week High | $63.90 | $151.02 |
Technical Indicators
Market Signals| Indicator | VRNS | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 52.75 | 51.96 |
| Support Level | $31.16 | $82.48 |
| Resistance Level | $49.54 | $95.59 |
| Average True Range (ATR) | 1.95 | 4.71 |
| MACD | -0.08 | 0.99 |
| Stochastic Oscillator | 69.51 | 85.06 |
Price Performance
Historical ComparisonAbout VRNS Varonis Systems Inc.
Varonis Systems is a cybersecurity vendor focused on data privacy and security. The firm is currently undergoing a cloud transition as it weans its on-premises customers over to its cloud products that are delivered as software-as-a-service. The New York-based firm was founded in 2005 and went public in 2014.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.